

บรรณานุกรม

- กลุ่มงานพัฒนาคุณภาพบริการ และวิชาการ. 2544. "รายงานประจำปี 2544". โรงพยาบาลกระบี่ :
กลุ่มงานพัฒนาคุณภาพบริการ และวิชาการ. (สำเนา)
- กลุ่มงานเภสัชกรรม. 2544. "บัญชีรายการยา โรงพยาบาลกระบี่ 2544-45". โรงพยาบาลกระบี่ :
กลุ่มงานเภสัชกรรม.
- กัลยา วานิชย์บัญชา. 2545. การใช้ SPSS for Windows ในการวิเคราะห์ข้อมูล. กรุงเทพฯ : ซีเค
แอนด์ เอส โฟโต้สตูดิโอ.
- กัลยา วานิชย์บัญชา. 2544. การวิเคราะห์หัตถ์แปรหลายตัวด้วย SPSS for Windows. กรุงเทพฯ : โรง-
พิมพ์แห่งจุฬาลงกรณ์มหาวิทยาลัย.
- ธีระพงษ์ ตันทิวีเชียร. 2547. "Septis and Septic Shock", ใน ภาวะติดเชื้อ molecular/ cellular and
clinical basis, หน้า 986-1001. สมเกียรติ วัฒนศิริชัยกุล, บรรณาธิการ. กรุงเทพฯ :
เมดิคัล ครีเอทีฟ.
- พรรณพิศ สุวรรณกุล. 2539. "Update in Antibiotic Use : Switch Therapy", สมาคมศิษย์เก่ากรุง-
เทพฯ : สมาคมศิษย์เก่าแพทย์จุฬาลงกรณ์.
- Ahkee, S.; Smith, S.; Newman, D.; Ritter, W.; Burke, J. and Ramirez, JA. 1997. "Early switch
from intravenous to oral antibiotics in hospitalized patients with infections: a 6-
month prospective study", *Pharmacother.* 17, 569-75.
- Al-Eidan, FA.; McElnay, JC.; Scott, MG.; Kearney, MP.; Troughton, KEU. and Jenkins, J. 1999.
"Sequential antimicrobial therapy: treatment of severe lower respiratory tract
infections in children", *J Antimicrob Chemother.* 44, 709-15.
- Amodio-Groton, M.; Madu, A.; Madu, CN.; Briceland, LL.; Seligman, M.; McMaster, P. and
Miller, MH. 1996. "Sequential parenteral and oral ciprofloxacin regimen versus
parenteral therapy for bacteremia: a pharmacoeconomic analysis", *Ann
Pharmacother.* 30, 596-602.
- Bartlett, JG. 2001. "Guidelines for the management of adults with community-acquired
pneumonia", *Am J Respir Crit Care Med.* 163, 1730-4.
- Bernstein, JM. 1999. "Treatment of community-acquired pneumonia-*IDS*A guidelines", *Chest.*
115, 9S-13S.
- Bouza, E.; Diaz-Lopez, MD.; Bernaldo de Quiros, JCL. and Rodriguez-Creixems, M. 1989.

- "Ciprofloxacin in patients with bacteremic infections", *Am J Med.* 87, 228S-31S (suppl 5A) .
- Bradley, JS.; Ching, DK. and Hart, C. 1987. "Invasive bacterial disease in childhood: efficacy of oral antibiotic therapy following short course parenteral therapy in non-central nervous system infections", *Pediatr Infect Dis J.* 6, 821-5.
- Brambilla, C.; Kastanakis, S. and Knight, S. 1992. "Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections", *Eur J Clin Microb Infect Dis.* 11, 118-24.
- Brande, PV.; Vondra, V.; Vogel, F.; Schlaeffer, F.; Staley, H. and Holmes, C. 1997. "Sequential therapy with cefuroxime followed by cefuroxime axetil in community acquired pneumonia", *Chest.* 112, 406-15.
- Chan, R.; Hemeryck, L.; O'Regan, M.; Clancy, L. and Feely, J. 1995. "Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial", *BMJ.* 310, 1360-2.
- Chayakul, P. and Yipintsoi, T. 1993a. "Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis", *J Med Assoc Thai.* 76, 559-63.
- Chayakul, P.; Krisanapan, S. and Kalnauwakul, S. 1993b. "Sequential intravenous/oral ciprofloxacin in the treatment of severe multiresistant gram-negative infections", *J Med Assoc Thai.* 76, 35-40.
- Chrysanthopoulos, AJ.; Starakis, JC.; Skoutelis, AT. and Bassaris, HP. 1989. "Brief report: sequential intravenous/oral therapy with ciprofloxacin in severe infection", *Am J Med.* 87, 225S-7S (suppl 5A) .
- Cohn, SM.; Lipsett, PA.; Buchman, TG.; Cheadle, WG.; Milsom, JW.; O'Marro, S.; Yellin, AE.; Jungerwirth, S.; Rochefort, EV.; Haverstock, DC.; Kowalsky, SF. and the Intra-Abdominal Study Group. 2000. "Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections", *Ann Surg.* 232, 254-62.
- Cooke, J.; Cairns, CJ.; Tillotson, GS.; Conner, S.; Lewin, SKM.; Nicholls, J.; Tredree, RL.; Willis, JV. and Hitchings, CR. 1993. "Comparative clinical, microbiology, and economic audit of the use of oral ciprofloxacin and parenteral antimicrobials",

- Ann Pharmacother. 27, 785-9.
- Craig, WA. and Andes, DR. 1995a. "Parenteral versus oral antibiotic therapy", *Med Clin North Am.* 79, 497-508.
- Craig, WA. and Ebert, SC. 1991b. "Killing and regrowth of bacteria in vitro: a review", *Scand J Infect Dis.* 63-70 (suppl 74) .
- Cunha, BA. 1996a. "Community-acquired pneumonia cost-effective antimicrobial therapy", *Postgrad Med.* 99, 109-19, 122.
- Cunha, BA. 1997b. "Intravenous-to-oral antibiotic switch therapy", *Postgrad Med.* 101, 111-28.
- Dagan, R.; Syrogiannopoulos, G.; Ashkenazi, S.; Engelhard, D.; Einhorn, M.; Gatzola-Karavelli, M.; Shalit, I. and Amir, J. 1994. "Parenteral-oral switch in the management of paediatric pneumonia", *Drugs.* 47, 43-51 (suppl 3) .
- Davey, P. 1999. "Cost effectiveness of quinolones in hospitals and the community", *Drugs.* 58, 71-7 (suppl 2) .
- Dean, NC. 1999. "Use of prognostic scoring and outcome assessment tools in the admission decision for community-acquired pneumonia", *Clin Chest Med.* 20, 521-9.
- Dresser, LD.; Niederman, MS. and Paladino, JA. 2001. "Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia", *Chest.* 119, 1439-48.
- Drusano, GL. 1988. "Role of pharmacokinetics in the outcome of infections", *Antimicrob Agents Chemother.* 32, 289-97.
- Ehrenkranz, NJ.; Nerenberg, DE.; Shultz, JM. and Slater, KC. 1992. "Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay", *Infect Control Hosp Epidemiol.* 13, 21-32.
- Feist, H. 1991. "Sequential therapy with I.V. and oral ofloxacin in lower respiratory tract infections: a comparative study", *Infection.* 19, S380-3 (suppl 7) .
- Fish, DN. 2005. "Urinary tract infections", In *Applied therapeutics: the Clinical Use of Drugs*, p. 64-1-22. Koda-Kimble, MA.; Young, LY.; Kradjan, WA. and Guglielmo, BJ., eds. USA : Lippincott Williams & Wilkins.
- Frighetto, L.; Nickoloff, D.; Martinusen, SM.; Mamdani, FS. and Jewesson, PJ. 1992.

- "Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital", *Ann Pharmacother.* 26, 1447-51.
- Fudge, KA.; Moore, KA.; Schneider, DN.; Sherrin, TP. and Wellman, GS. 1993. "Change in prescribing patterns of intravenous histamine₂-receptor antagonists results in significant cost saving without adversely affecting patient care", *Ann Pharmacother.* 27, 232-7.
- Gangji, D.; Jacobs, F.; de Jonckheer, J.; Coppens, L.; Serruys, E.; Hanotte, F.; Motte, S. and Thys, JP. 1989. "Brief report: randomized study of intravenous versus sequential intravenous/oral regimen of ciprofloxacin in the treatment of gram-negative septicemia", *Am J Med.* 87, 5A-206S-8S (suppl 5A).
- Gault, PL.; Carron, WC.; Ching, WT. and Mayer, RD. 1989. "Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections", *Am J Med.* 87, 169S (suppl 5A).
- Gelone, SP. and O'Donnell, JA. 2005. "Respiratory tract infections", In *Applied therapeutics: the Clinical Use of Drugs*, p. 60-1-30. Koda-Kimble, MA.; Young, LY.; Kradjan, WA. and Guglielmo, BJ., eds. USA : Lippincott Williams & Wilkins.
- Gentry, LO. and Koshedl, A. 1989a. "Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram negative infections of the skin and skin structure", *Am J Med.* 87, 132S (suppl 5A).
- Gentry, LO. and Rodriguez-Gomez, G. 1991b. "Ofloxacin versus parenteral therapy for chronic osteomyelitis", *Antimicrob Agents Chemother.* 35, 538-41.
- Gentry, LO.; Ramirez, CH.; Rodriguez-Noriega, E.; Thadelpalli, H.; Rosal, PL. and Ramirez, C. 1989c. "Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections", *Arch Intern Med.* 149, 2579.
- Gentry, LO.; Rodriguez-Gomez, G. and Kohler, RB. 1998d. "Parenteral followed by oral ofloxacin for nosocomial pneumonia and community acquired pneumonia requiring hospitalization", *Chest.* 113, S211-8.
- Gentry, LO.; Rodriguez-Gomez, G.; Zeuff, BJ.; Khoshodel, A. and Price, M. 1989e. "A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections", *Am J Med.* 87, 57S (suppl 6C).

- Halm, EA.; Fine, MJ.; Marrie, TJ.; Coley, CM.; Kapoor, WN.; Obrosky, DS. and Singer, DE. 1998. "Time to clinical stability in patients hospitalized with community-acquired pneumonia", *JAMA*. 279, 1452-7.
- Hendrickson, JR. and North, DS. 1995. "Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil", *Ann Pharmacother*. 29, 561-5.
- Houck, PM.; MacLehose, RF.; Niederman, MS. and Lowery, JK. 2001. "Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states 1993, 1995, and 1997", *Chest*. 119, 1420-6.
- Hunter, KA. and Dormaier, GK. 1995. "Pharmacist-managed intravenous to oral step-down program", *Clin Ther*. 17, 534-40.
- Ishida, T.; Hashimoto, T.; Arita, M.; Ito, I. and Osawa, M. 1998. "Etiology of community-acquired pneumonia in hospitalized patients a 3-year prospective study in Japan", *Chest*. 114, 1588-93.
- John Jr, JF. and Fishman, NO. 1997. "Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital", *CID*. 24, 471-85.
- Khajalia, R.; Driicek, M. and Vetter, N. 1990. "A comparative study of ofloxacin and amoxicillin/clavulanate in hospitalized patients with lower respiratory tract infections", *J Antimicrob Chemother*. 26, 83-91 (suppl D).
- Khan, FA. and Basir, R. 1989. "Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections", *Chest*. 96, 528-37.
- Krumpe, PE.; Cohn, S.; Garreltes, J.; Ramirez, J.; Coulter, H.; Haverstock, D.; Echols, R. and the Ciprofloxacin Study Group. 1999. "Intravenous and oral mono-or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy", *J Antimicrob Chemother*. 43, 117-28 (suppl A) .
- Laing, RBS.; Mackenzie, AR.; Shaw, H.; Gould, IM. and Douglas, JG. 1998. "The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards", *J Antimicrob Chemother*. 42, 107-11.
- Low, DE. 1995. "Assessment of the use of cefixime for switch therapy", *Infection*. 23, S91-S94.
- MacGregor, RR. and Graziani, AL. 1997. "Oral administration of antibiotics: a rational

- alternative to the parenteral route", *CID*. 24, 457-67.
- Malfair, SC.; Frighetto, L.; Nickoloff, DM.; Martinusen, SM. and Jewesson, PJ. 1996. "Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program", *Ann Pharmacother*. 30, 337-42.
- Mandell, LA. 1999. "Antibiotic therapy for community-acquired pneumonia", *Clin Chest Med*. 20, 589-98.
- Marrie, TJ. ; Lau, CY.; Wheeler, SL.; Wong, CJ.; Vandervoort, MK. and Feagan, BG. 2000. "A controlled trial of a critical pathway for treatment of community-acquired pneumonia", *JAMA*. 283, 749-55.
- McCormack, JP. and Brown, GR. 2005. "Traumatic skin and soft tissue infections", In *Applied therapeutics: the Clinical Use of Drugs*, p. 67-1-11. Koda-Kimble, MA.; Young, LY.; Kradjan, WA. and Guglielmo, BJ., eds. USA : Lippincott Williams & Wilkins.
- Nathwani, D. 1998. "Sequential switch therapy for lower respiratory tract infections a European perspective", *Chest*. 113, 211S-8S.
- Neu, HC. 1989. "New oral and parenteral quinolones", *Am J Med*. 87, 5A-283S-7S (suppl 5A).
- Norsavan, P.; Chindavijak, B. and Vibhagool, A. 2001. "Conversion from intravenous route to oral route of antimicrobial therapy", *J Infect Dis Antimicrob Agents*. 18, 63-70.
- Offman, E.; Varin, F.; Nolan, T.; Bayliff, CD.; Bombassaro, AM. and McCormack, DG. 2000. "Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia", *Chest*. 117, 1090-3.
- Omidvari, K.; de Boisblanc, BP.; Karam, G.; Nelson, S.; Haponik, E. and Summer, W. 1998. "Early transition to oral antibiotic therapy for community-acquired pneumonia : duration of therapy, clinical outcomes, and cost analysis", *Respir Med*. 92, 1032-9.
- Paladino, JA. 1997a. "Pharmacoeconomics of antimicrobial therapy", *Am J Health-Syst Pharm*. 56, S25-8 (suppl 3) .
- Paladino, JA.; Sperry, HE.; Backes, JM.; Gelber, JA.; Serrienne, DJ.; Cumbo, TJ. and Schentag, JJ. 1991b. "Clinical and economic evaluation of oral ciprofloxacin after an

- abbreviated course of intravenous antibiotics", *Am J Med.* 91, 462-70.
- Partsch, DJ. and Paladino, JA. 1997. "Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy", *Ann Pharmacother.* 31, 1137-45.
- Peacock, JE.; Pegram, PS.; Weber, SF. and Leone, PA. 1989. "Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections", *Am J Med.* 87, 185S (suppl 5A).
- Przybylski, KG.; Rybak, MJ.; Martin, PR.; Weingarten, CM.; Zaran, FK.; Stevenson, JG. and Levine, DP. 1997. "A pharmacist-initiated program of intravenous to oral antibiotic conversion", *Pharmacother.* 17, 271-6.
- Quintiliani, R.; Cooper, BW.; Briceland, LL. and Nightingale, CH. 1987. "Economic impact of streamlining antibiotic administration", *Am J Med.* 82, 391-4 (suppl 4A) .
- Raasch, RH. 2005. "Osteomyelitis and septic arthritis", In *Applied therapeutics: the Clinical Use of Drugs*, p. 66-1-13. Koda-Kimble, MA.; Young, LY.; Kradjan, WA. and Guglielmo, BJ., eds. USA : Lippincott Williams & Wilkins.
- Ramirez, JA. 1994a. "Advances in antibiotic use: switch therapy", *Curr Ther Res.* 55, 30-4 (suppl A) .
- Ramirez, JA. 1998b. "Switch therapy with β -lactam/ β -lactamase inhibitors in patients with community-acquired pneumonia", *Ann Pharmacother.* 32, S22-6 (suppl) .
- Ramirez, JA. and Bordon, J. 2001c. "Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired *Streptococcus pneumoniae* pneumonia", *Arch Intern Med.* 161, 848-50.
- Ramirez, JA.; Srinath, L.; Ahkee, S.; Huang, A. and Raff, MJ. 1995d. "Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia", *Arch Intern Med.* 155, 1273-6.
- Ramirez, JA.; Vargas, S.; Ritter, GW.; Brier, ME.; Wright, A.; Smith, S.; Newman, D.; Burke, J.; Mushtaq, M. and Huang, A. 1999e. "Early switch from intravenous to oral antibiotics and early hospital discharge a prospective observational study of 200 consecutive patients with community-acquired pneumonia", *Arch Intern Med.* 159, 2449-54.

- Rhew, DC.; Hackner, D.; Henderson, L.; Ellrodt, AG. and Weingarten, SR. 1998a. "The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy", *Chest*. 113, 142-6.
- Rhew, DC.; Riedinger, MS.; Sandhu, M.; Bowers, C.; Greengold, N. and Weingarten, SR. 1998 b. "A prospective, multicenter study of a pneumonia practice guideline", *Chest*. 114, 115-9.
- Rhew, DC.; Tu, GS.; Ofman, J.; Henning, JM.; Richards, MS. and Weingarten, SR. 2001c. "Early switch and early discharge strategies in patients with community-acquired pneumonia a meta-analysis", *Arch Intern Med*. 161, 722-7.
- Roberts, BL. 1997. "Decentralizing an i.v.-to-oral conversion program", *Am J Health-Syst Pharm*. 54, 524-5.
- Rosenblatt, JE. 1991. "Laboratory tests used to guide antimicrobial therapy", *Mayo Clin Proc*. 66, 942-8.
- Sevinc, F.; Prins, JM.; Koopmans, RP.; Langendijk, PNJ.; Bossuyt, PMM.; Dankert, J. and Speelman, P. 1999. "Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital", *J Antimicrob Chemother*. 43, 601-6.
- Shann, F.; Barker, J. and Poore, P. 1985. "Chloramphenicol alone versus chloramphenicol plus penicillin for severe pneumonia in children", *Lancet*. 28, 684-5.
- Siegel, RE. 1999a. "Strategies for early discharge of the hospitalized patient with community-acquired pneumonia", *Clin Chest Med*. 20, 599-605.
- Siegel, RE.; Halpern, NA.; Almenoff, PL.; Lee, A.; Cashin, R. and Greene, JG. 1996b. "A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia", *Chest*. 110, 965-71.
- Sutherland, R. 1995. " β -lactam/ β -lactamase inhibitor combinations: development, antibacterial activity and clinical applications", *Infection*. 23, 191-200.
- Thys, JP.; Jacobs, F. and Motte, S. 1989. "Quinolones in the treatment of lower respiratory tract infections", *Rev Infect Dis*. 11, S1212-9.
- Vogel, F. 1995a. "Sequential therapy in the hospital management of lower respiratory infections", *Am J Med*. 99, 6B-14S-9S (suppl 6B) .

- Vogel, F. and the multicenter trial group. 1994b. "Efficacy and tolerance of cefotaxime followed by oral cefixime versus cefotaxime alone in patients with lower respiratory tract infections", *Curr Ther Research*. 55, 42-8 (suppl A) .
- Vogelman, B.; Gudmundsson, S.; Leggett, J.; Turnidge, J.; Ebert, S. And Craig, WA. 1988. "Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model", *J Infect Dis*. 158, 831-47.
- Warren, JW.; Horne, LM.; Hebel, JR.; Marvel, RP.; Keay, SK. and Chai, TC. 2000. "Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis", *J Urol*. 163, 1685-8.
- Waterer, GW.; Jennings, SG. and Wunderink, RG. 1999. "The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia", *Chest*. 116, 1278-81.
- Weingarten, SR.; Riedinger, MS.; Hopson, P.; Noah, MS.; Johnson, B.; Giugliano, G.; Norian, J.; Belman, MJ. And Ellrodt, AG. 1996a. "Evaluation of a pneumonia practice guideline in an interventional trial", *Am J Respir Crit Care Med*. 153, 1110-5.
- Weingarten, SR.; Riedinger, MS.; Varis, G.; Noah, MS.; Belman, MJ.; Meyer, RD. and Ellrodt, AG. 1994b. "Identification of low-risk hospitalized patients with pneumonia implications for early conversion to oral antimicrobial therapy", *Chest*. 105, 1109-15.
- Wilcox, MH. 1998. "Implementation of sequential therapy programs-a microbiologist's view", *J Infect*. 37, 51-4 (suppl 1) .
- Woodhead, M. 1998. "Community-acquired pneumonia guidelines-an international comparison a view from Europe", *Chest*. 113, 183S-7S.
- Zamin, MT.; Pitre, MM. and Conly, JM. 1997. "Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility", *Ann Pharmacother*. 31, 564-70.
- Zhanel, GG.; Hoban, DJ. and Harding, GKM. 1991. "The postantibiotic effect: a review of in vitro and in vivo data", *Ann Pharmacother*. 25, 153-63.
- Zuch, P.; Rio, Y. and Ichou, F. 1990. "Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia", *J Antimicrob Chemother*. 26, 71-7 (suppl E).